This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Public Health  • Tobacco  • Quality of Life  • Rheumatology  • Rheumatology, Other  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jeffrey P. Callen, MD

Arch Dermatol. 2009;145(3):316-319.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of the Archives there are 6 articles on the subject of cutaneous lupus erythematosus (CLE) that provide dermatologists with new insights and offer us practical advice about the manner in which we might care for patients who present to our clinics and offices with cutaneous lesions of lupus erythematosus (LE). I reached out to several of the authors for answers to some of the questions that developed as I reviewed this group of articles systemically rather than individually. The answers that I received to some of my questions are within this editorial. As part of the process of preparing this editorial, I have included some practical information about how I evaluate and treat patients with CLE in my clinical practice and conclude with what I see are unanswered questions that remain for future study.

In 2000, Ackerman et al^1(p336) wrote, "Perhaps no subject . . . [Full Text of this Article]

WHICH TYPES OF CLE LESIONS ARE MOST COMMONLY SEEN?


WHAT IS THE RISK OF DEVELOPING SLE FOR A PATIENT WITH CUTANEOUS LESIONS, AND DOES OUR THERAPY LOWER THE CHANCE OF PROGRESSION?

HOW DOES THE PRESENCE OF CLE HAVE AN IMPACT ON A PATIENT’S QUALITY OF LIFE, AND DOES TREATMENT HAVE AN EFFECT ON IMPROVING PATIENTS WHOSE DISEASE HAS HAD AN IMPACT ON THEIR LIVES?

HOW OFTEN AND WHICH DRUGS ARE INVOLVED IN EXACERBATION OF, OR INDUCTION OF, CLE?

WHAT IS THE ROLE OF SMOKING IN PATIENTS WITH CLE, AND ARE SMOKING CESSATION PROGRAMS EFFECTIVE AS PART OF THE TREATMENT OF PATIENTS WITH CLE?

IS TLE A MISNOMER?

CONCLUSIONS AND FUTURE QUESTIONS

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Lupus Erythematosus Tumidus: Response to Antimalarial Treatment in 36 Patients With Emphasis on Smoking
Alexander Kreuter, Renata Gaifullina, Christian Tigges, Julia Kirschke, Peter Altmeyer, and Thilo Gambichler
Arch Dermatol. 2009;145(3):244-248.
ABSTRACT | FULL TEXT  

Incidence of Cutaneous Lupus Erythematosus, 1965-2005: A Population-Based Study
Olayemi Durosaro, Mark D. P. Davis, Kurtis B. Reed, and Audrey L. Rohlinger
Arch Dermatol. 2009;145(3):249-253.
ABSTRACT | FULL TEXT  

Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions: Prospective Enrollment of 114 Patients
Siamak Moghadam-Kia, Katherine Chilek, Elizabeth Gaines, Melissa Costner, Mathew E. Rose, Joyce Okawa, and Victoria P. Werth
Arch Dermatol. 2009;145(3):255-260.
ABSTRACT | FULL TEXT  

Lenalidomide for the Treatment of Resistant Discoid Lupus Erythematosus
Asha Shah, Joerg Albrecht, Zuleika Bonilla-Martinez, Joyce Okawa, Mathew Rose, Misha Rosenbach, and Victoria P. Werth
Arch Dermatol. 2009;145(3):303-306.
ABSTRACT | FULL TEXT  

Subacute Cutaneous Lupus Erythematosus Associated With Capecitabine Monotherapy
Neil F. Fernandes, Misha Rosenbach, Rosalie Elenitsas, and Joseph M. Kist
Arch Dermatol. 2009;145(3):340-341.
EXTRACT | FULL TEXT  

Tumid Lupus Erythematosus at the Site of a Scar
Gregory Perez, John P. Kowalczyk, Dwayne Montie, and Carlos H. Nousari
Arch Dermatol. 2009;145(3):343-344.
EXTRACT | FULL TEXT